|
Delayed
NSE India S.E.
11:01:38 25/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,914.80 INR | +0.25% |
|
+2.17% | +11.40% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,583B 47.86B 41.02B 38.37B 35.08B 66.2B 66.9B 454B 177B 2,301B 180B 176B 7,614B | P/E 2027 * |
35.2x | P/E 2028 * | 29.8x |
|---|---|---|---|---|---|
| Enterprise Value | 4,304B 44.95B 38.52B 36.03B 32.94B 62.17B 62.83B 426B 166B 2,161B 169B 165B 7,150B | EV / Sales 2027 * |
6.61x | EV / Sales 2028 * | 5.81x |
| Free-Float |
44.39% | Yield 2027 * |
0.89% | Yield 2028 * | 1.04% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.30% | ||
| 1 week | +2.17% | ||
| Current month | -3.76% | ||
| 1 month | -2.94% | ||
| 3 months | +4.08% | ||
| 6 months | +8.59% | ||
| Current year | +11.40% |
| 1 week | 1,871 |  | 1,923 |
| 1 month | 1,868.3 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | +2.17% | +15.63% | +73.16% | 47.86B | |
| -0.98% | +0.42% | +50.75% | +124.01% | 40.33B | |
| -1.13% | -0.68% | -11.23% | +17.53% | 12.13B | |
| -0.76% | -1.81% | +7.06% | +74.07% | 11.5B | |
| +0.19% | 0.00% | +30.98% | +154.90% | 9.1B | |
| 0.00% | +2.54% | +24.70% | +46.08% | 7.82B | |
| +0.61% | +0.76% | +47.64% | -10.83% | 7.22B | |
| +0.54% | +4.68% | +23.35% | +226.31% | 7.05B | |
| -3.24% | -9.97% | -40.05% | +13.62% | 5.24B | |
| -1.24% | -4.62% | +34.82% | +108.60% | 4.67B | |
| Average | -0.19% | -0.50% | +18.37% | +82.75% | 15.29B | |
| Weighted average by Cap. | -0.20% | +0.64% | +24.04% | +87.84% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.8B 5.83B 5.45B 4.98B 9.4B 9.5B 64.49B 25.08B 327B 25.52B 24.97B 1,081B | 729B 7.61B 6.52B 6.1B 5.58B 10.53B 10.64B 72.2B 28.07B 366B 28.57B 27.96B 1,211B |
| Net income | 130B 1.36B 1.16B 1.09B 996M 1.88B 1.9B 12.9B 5.01B 65.36B 5.1B 4.99B 216B | 154B 1.61B 1.38B 1.29B 1.18B 2.23B 2.25B 15.28B 5.94B 77.42B 6.05B 5.92B 256B |
| Net Debt | -279B -2.91B -2.5B -2.34B -2.14B -4.03B -4.07B -27.65B -10.75B -140B -10.94B -10.7B -464B | -349B -3.65B -3.13B -2.92B -2.67B -5.04B -5.1B -34.59B -13.45B -175B -13.69B -13.4B -580B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/08/26 | ₹1,914.80 | +0.25% | 528,689 |
| 24/08/26 | ₹1,910.00 | +0.40% | 2,317,987 |
| 21/08/26 | ₹1,902.40 | -0.08% | 1,491,953 |
| 20/08/26 | ₹1,904.00 | +0.21% | 893,691 |
| 19/08/26 | ₹1,900.00 | +1.33% | 1,566,692 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
